



Universiteit
Leiden
The Netherlands

Arteriolar C4d in IgA nephropathy: a cohort study

Faria, B.; Canao, P.; Cai, Q.Q.; Henriques, C.; Matos, A.C.; Poppelaars, F.; ... ; Seelen, M.A.

Citation

Faria, B., Canao, P., Cai, Q. Q., Henriques, C., Matos, A. C., Poppelaars, F., ... Seelen, M. A. (2020). Arteriolar C4d in IgA nephropathy: a cohort study. *American Journal Of Kidney Diseases*, 76(5), 669-678. doi:10.1053/j.ajkd.2020.03.017

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3185006>

Note: To cite this publication please use the final published version (if applicable).

Arteriolar C4d in IgA Nephropathy: A Cohort Study

Bernardo Faria, Pedro Canão, Qingqing Cai, Carla Henriques, Ana Cristina Matos, Felix Poppelaars, Mariana Gaya da Costa, Mohamed R. Daha, Roberto Silva, Manuel Pestana, and Marc A. Seelen



Rationale & Objective: Glomerular C4d (C4dG) as an indicator of the lectin pathway of complement activation in immunoglobulin A nephropathy (IgAN) has been associated with more severe kidney damage. Recent studies have suggested that vascular lesions in IgAN biopsy specimens with complement deposition are also associated with disease progression. We aimed to study the clinical significance of arteriolar C4d (C4dA) in IgAN kidney biopsy tissue.

Study Design: Retrospective cohort study.

Setting & Participants: Kidney biopsy specimens from 126 adults with IgAN diagnosed by Oxford classification criteria were stained using immunohistochemistry and classified according to C4dG and C4dA deposition. Additionally, vascular lesions including acute and chronic microangiopathy, arteriolar hyalinosis, and arterial intima fibrosis were characterized.

Predictor: C4dA.

Outcome: Progressive kidney disease, defined as a decline in estimated glomerular filtration rate by $\geq 50\%$ or occurrence of kidney failure.

Analytical Approach: The association of C4dA and C4dG with baseline clinical and histologic

characteristics, as well as progressive kidney disease, were assessed with survival analysis using multivariable Cox regression analysis.

Results: C4dA was identified in 21 (17%) patients and was associated with mean arterial pressure, arterial intima fibrosis, and chronic microangiopathy. C4dA was also significantly associated with C4dG and both were associated with progressive kidney disease. In regression analysis, C4dA remained significantly associated with progressive kidney disease after adjusting for other significant predictors, including baseline estimated glomerular filtration rate, mean arterial pressure, and the presence of crescents.

Limitations: Findings based on the retrospective evaluation of a single center's experience, limited number of events, a small number of patients with a broad range of kidney disease stages, and use of immunohistochemistry rather than immunofluorescence to detect C4d.

Conclusions: C4dA is a potential biomarker for disease progression in IgAN. It should be further investigated in larger cohorts to determine the value of C4dA in improving prediction of IgAN disease progression.

Complete author and article information provided before references.

Correspondence to B. Faria (faria_bernardo@yahoo.com)

Am J Kidney Dis. 76(5): 669-678. Published online May 19, 2020.

doi: 10.1053/j.ajkd.2020.03.017

© 2020 by the National Kidney Foundation, Inc.

Immunoglobulin A (IgA) nephropathy (IgAN) is the most common glomerulonephritis worldwide.¹ Up to 40% of IgAN cases will progress to kidney failure with replacement therapy within 20 years of diagnosis.² The use of immunosuppression in IgAN has been subject to controversy and concerns. Although the addition of immunosuppressive therapy to supportive care seems to reduce proteinuria, the impact on progressive kidney disease in patients with IgAN has been inconsistent.³⁻⁵ Moreover, immunosuppression has substantial side effects, including the risk for severe infection.⁵ Therefore, biomarkers identifying subgroups of patients with IgAN with poor prognosis that might benefit from more aggressive forms of treatment are needed.

Although not yet widely used in clinical practice, several studies have shown that glomerular C4d (C4dG) is a valuable biomarker associated with disease progression in IgAN.⁶ Moreover, C4dG identifies patients who are at risk for progression at an early stage of the disease,⁷ and its predictive value remains after adjustment for other established immunohistologic biomarkers.⁸ A mechanistic explanation for the mesangial deposition of C4d is the glomerular activation of the lectin pathway of complement.^{9,10} Complement activation has also been

documented in urine and serum of patients with IgAN,^{11,12} whereas variants in complement genes have been shown to affect IgAN risk and prognosis.^{13,14} Consequently, clinical trials have been initiated with different complement inhibitors in IgAN.¹⁵

The vascular compartment is neglected by the Oxford pathologic classification because its significance in predicting kidney outcomes is uncertain.¹⁶⁻¹⁹ Nevertheless, the impact of risk factors for vascular disease on the progression of IgAN has been shown in numerous studies.^{5,19-21} Additionally, microangiopathic lesions in IgAN biopsy specimens have been associated with worse prognosis.^{22,23} Interestingly, C4d has been proposed as a marker of thrombotic microangiopathy in various kidney diseases, including IgAN.^{24,25} We therefore aimed to investigate the significance of arteriolar C4d (C4dA) in a cohort of patients with IgAN and compare it with clinical and histologic markers of disease progression.

Methods

Patients

We reviewed kidney pathology archives from January 2001 to December 2017 at Centro Hospitalar Universitário

PLAIN-LANGUAGE SUMMARY

Immunoglobulin A nephropathy (IgAN) is a challenging disease for nephrologists due to its frequency, heterogeneity, and potential to cause kidney failure. Recent studies have demonstrated that glomerular C4d deposition representing activation of the lectin complement pathway can be used to identify a subgroup of patients with poor outcomes. However, the vascular compartment in IgAN biopsy specimens has not been fully examined for C4d deposition. Consequently, we studied the clinical relevance of arteriolar C4d deposition and found it to be significantly associated with disease progression even after controlling for established predictors and glomerular C4d. These findings suggest that C4d deposition in the vascular compartment of the kidneys may be a useful prognostic biomarker of IgAN disease progression and enable a more personalized approach to this disease.

de São João in Portugal to identify patients who had IgAN diagnosed by initial kidney biopsy. The following information at the time of the kidney biopsy was recorded: age, sex, systolic and diastolic blood pressure, use of antihypertensive medication up to 1 year before the referral to the nephrologist, total cholesterol level, triglyceride level, high- and low-density lipoprotein cholesterol levels, use of lipid-lowering medication, smoking status, proteinuria, serum creatinine level, history of macroscopic hematuria, comorbid conditions, and number of glomeruli in the kidney biopsy specimen. Kidney disease progression and postbiopsy use of renin-angiotensin system blockade and/or immunosuppressive therapy record were retrospectively reviewed. Inclusion criteria were absence of Henoch-Schönlein purpura diagnosis or other conditions such as diabetes mellitus, liver disease, lupus nephritis, vasculitis, or atypical hemolytic uremic syndrome and availability of paraffin-embedded kidney biopsy specimens (with ≥ 8 glomeruli).

The Centro Hospitalar Universitário de São João Ethics Committee reviewed and approved the use of patients' biopsy specimens for the purpose of this study without the need to obtain informed consent. The study was conducted in accordance with the principles originating from the Declaration of Helsinki.

Clinical Definitions

Estimated glomerular filtration rate (eGFR) was determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.²⁶ Progressive kidney disease was defined as a decline of at least 50% in eGFR or progression to kidney failure during the follow-up period.²⁷ Hypertension was defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg and/or use of antihypertensive medication

and further classified as hypertension at the time of biopsy (hypertension at biopsy) or hypertension diagnosed 1 or more year before the nephrology consultation (previous hypertension). Dyslipidemia was defined as the presence of either total cholesterol level ≥ 200 mg/dL, low-density lipoprotein cholesterol level ≥ 130 mg/dL, high-density lipoprotein cholesterol level < 40 mg/dL in men and < 50 mg/dL in women, triglyceride level ≥ 150 mg/dL, or use of antidyslipidemic medication. Shortly before the kidney biopsy, 24-hour urine was collected to determine proteinuria. End points were recorded until May 2018 or until the first progression to kidney failure (eGFR < 15 mL/min/1.73 m², dialysis, or transplantation). There was no loss to follow-up and no deaths occurred during follow-up.

Kidney Pathologic Evaluation

Paraffin-embedded tissue from kidney biopsies was stained with hematoxylin and eosin, periodic acid-Schiff, silver methenamine, and Masson trichrome. Direct immunofluorescence was used to detect deposition of IgG, IgA, IgM, C3, C1q, and fibrinogen. Sections for light microscopy were graded according to the Oxford classification of IgAN (MEST-C score).^{16,28}

Further, kidney biopsy specimens were analyzed for vascular lesions and classified as previously described.²³ In brief, "acute" microangiopathic was defined as endothelial cell swelling, subintimal edema, and arteriolar thrombosis and/or fibrinoid necrosis, while lesions with arterial "onion skin" lesion (fibrous intimal thickening with concentric lamination) were considered "chronic." In addition, general microangiopathic lesions was defined as the presence of either or both lesions. Arteries and arterioles were also evaluated for arterial intimal fibrosis (defined as thickening of the arterial wall and narrowing of the vascular lumen produced by fibrotic intimal thickening and replication of the internal elastic lamina)²⁹ and arteriolar hyalinosis (defined as chronic arteriolar change with amorphous, glassy, and eosinophilic material observed in the walls of renal arterioles resulting in thickened arteriolar walls and luminal narrowing)³⁰ as previously described.²³ Each type of vascular lesion was simplified to absent or present to increase statistical power.

Immunoperoxidase staining was performed on formaldehyde-fixed sections deparaffinized in xylene and rehydrated in graded ethanol. Sections were stained with the polyclonal anti-human C4d (Biomedica), and antigen retrieval was performed in a microwave oven using trisethylenediamine tetraacetic acid buffer as antigen retrieval solution. For detection, the first step was blockade of endogenous peroxidases with hydrogen peroxide, followed by signal amplification with a horseradish peroxidase (HRP) kit (Universal HRP Multimer kit; Ventana Medical Systems). Diaminobenzidine was used as chromogen and hematoxylin as nuclear stain. Controls for immunohistochemistry (IHC) specificity were performed

by replacing the primary antibodies with irrelevant antisera. IHC score analysis was performed, with glomerular C4d recorded as negative (0) or positive (1). Patients were classified as “positive” when >25% of nonsclerotic glomeruli were positive for C4d, as described in Espinosa et al.³¹ For arteriolar C4d, the authors followed the same criteria as for glomeruli, classifying cases as “positive” if C4d IHC was present in >25% of arterioles.

Kidney biopsies from all patients were reviewed independently by 3 observers (P.C., Q.C., and B.F.) who were blinded to the clinical data. All disagreements were resolved by the senior pathologist (R.S.).

Statistical Analysis

Continuous variables are expressed as mean \pm standard deviation or median with interquartile range, while categorical variables are expressed as count and percentage.

Associations between categorical variables were tested using χ^2 test or Fisher exact test, as appropriate. Numerical variables were tested for normality. The t test was used to compare groups with respect to numerical variables if the normality assumption was met; otherwise, Mann-Whitney test was used. Associations were evaluated through the eta-squared statistic, the proportion of variance explained, for numerical outcomes, and through Cramér V coefficient, the strength of association, for categorical outcomes. Survival from progressive kidney disease was assessed using the Kaplan-Meier method and compared among C4dA and C4dG status using log-rank test. Associations between baseline variables and progressive kidney disease were estimated using Cox proportional hazards models.

Multivariable models were estimated to evaluate the association of C4dA IHC with progressive kidney disease while controlling for other significant variables. The reduced sample size and number of events limited the number of variables to be included in the multivariable model. Thus, initially variables associated with risk for progressive kidney disease were identified through simple Cox regression models. Second, a multiple regression model was constructed using a stepwise procedure, with variables for inclusion in a multiple regression model selected from identified variables in the first step.

The association of C4dA with progressive kidney disease was evaluated using 2 different approaches to build multiple models. The first approach involved selecting from C4dA and the other variables previously identified using a stepwise forward procedure. This approach led to a multiple Cox regression model with 5 variables, including C4dA. In the second approach, 2 multiple Cox regression models, one for significant clinical variables and the other for significant histologic variables, were constructed separately first and then combined into one. C4dA and C4dG were added separately to the previous models to evaluate the associations between these markers and progressive kidney disease. All nonsignificant variables were removed from the models. Models with C4dA IHC and models with C4dG IHC were compared using

the Akaike information criterion. Hazard ratios (HRs) for C4dA IHC and C4dG IHC and their 95% confidence intervals (CIs) from these models are reported. Harrell concordance index was used to assess and compare discrimination between the 2 models.^{32,33}

The association with progressive kidney disease of C4dA IHC, relative to C4dG IHC, was further evaluated using the likelihood ratio test. Two likelihood ratio tests were performed, each to test the multiple regression model with both C4dA IHC and C4dG IHC against the reduced simple model without one of these markers. A rejection of the null hypothesis (H_0) would suggest that the model with both C4dA IHC and C4dG IHC was preferred compared with the reduced model without one of these.

In Cox regression models the proportional hazards assumption was evaluated and if necessary, time-dependent coefficients were considered. Statistical analysis was undertaken using IBM SPSS Statistics (version 24) and R software (R Foundation for Statistical Computing). $P < 0.05$ was considered statistically significant.

Results

Patient, Clinical, and Pathologic Data

Isolated hematuria and/or proteinuria were the most common indication for a kidney biopsy (59.5%). Baseline eGFR was <60 mL/min/1.73 m² in 40.8% of patients, and baseline proteinuria > 1 g/d in 72% of the patients (Table 1). A total of 111 patients were treated with renin-angiotensin system blockade, and 29, with immunosuppression. During a median follow-up period of 4 (interquartile range, 2-6) years, progressive kidney disease developed in 32 patients (5.46/100 patient-years), of whom 31 had a decline in eGFR $\geq 50\%$ (5.29/100 patient-years) and 28 progressed to kidney failure (4.78/100 patient-years; Table S1).

Regarding baseline characteristics, older age, hypertension, higher mean arterial pressure (MAP), low serum C3:C4 ratio, lower eGFR, higher proteinuria, dyslipidemia, and smoking were all associated with progressive kidney disease (Table 2).

In histologic examination according to the Oxford classification, 83.3%, 49.2%, and 9.5% of patients' biopsy specimens were scored M1, S1, and E1, respectively; 27% of biopsy specimens were scored as having T1, and 4%, as T2. C1 and C2 were present in 11 (8.7%) patients, but only 1 case was classified as C2. Therefore, we aggregated the variable to the presence or absence of crescents, as previously described.^{23,34} Immunofluorescence data of kidney biopsies showed positivity for IgM in 43.7%, IgG in 23.0%, C3 in 73.8%, and C1q in 14.3%. IgM positivity, E1, T1, T2, and crescents were positively associated with progressive kidney disease (Table 2).

Among vascular lesions, acute, chronic, and general microangiopathic lesions were present in 18.3%, 15.9%, and 28.6% of cases, respectively. Furthermore, arterial intima fibrosis and arteriolar hyalinosis were found in 49% and 38% of patients, respectively. All vascular lesions were associated with progressive kidney disease (Table 2).

Table 1. Patient Baseline Characteristics and C4dA IHC Status

	All (N = 126)	C4dA IHC Status		P	Association
		Negative (n = 105)	Positive (n = 21)		
Clinical Data					
Age, y	42 ± 15	43 ± 16	39 ± 10	0.2 ^a	
Female sex	47 (37.3%)	38 (36.2%)	9 (43%)	0.6 ^b	
HTN at biopsy ^c	74 (58.7%)	59 (56.2%)	15 (71%)	0.2 ^b	
Previous HTN ^d	44 (34.9%)	35 (33.3%)	9 (43%)	0.5 ^b	
Mean arterial pressure, mm Hg	99.4 ± 15.2	97.6 ± 13.2	108.3 ± 21.0	0.03 ^a	0.069 ^e
RAS blockade	68 (54%)	58 (55.2%)	10 (48%)	0.5	
Previous macroscopic hematuria	44 (34.9%)	38 (36.2%)	6 (29%)	0.6 ^b	
eGFR, mL/min/1.73 m ²	69.1 ± 40.5	74.1 ± 40.1	44.0 ± 33.3	0.002 ^a	0.078 ^e
CKD stage				0.003 ^b	0.354 ^f
1	40 (31.7%)	39 (37.5%)	1 (5%)		
2	35 (27.8%)	29 (26.9%)	6 (29%)		
3	26 (20.6%)	22 (21.2%)	4 (19%)		
4	11 (8.7%)	7 (6.7%)	4 (19%)		
5	14 (11.1%)	8 (7.7%)	6 (29%)		
Proteinuria, g/d	1.83 [0.95-3.43]	1.65 [0.9-2.71]	3.48 [1.6-5.2]	0.01 ^g	0.051 ^h
Serum IgA, mg/dL	297 [231-391]	310 [249-404]	249 [225-302]	0.01 ^g	0.064 ^e
Serum C3:C4 ratio	4.10 [3.22-4.81]	4.29 [3.45-4.83]	3.23 [2.53-3.64]	0.005 ^g	0.049 ^h
Dyslipidemia ⁱ	45 (35.7%)	34 (32.4%)	11 (52%)	0.1 ^b	
Statin therapy	31 (24.6%)	26 (24.8%)	5 (24%)	0.9 ^b	
Smoker	21 (16.7%)	17(16.2%)	4 (19%)	0.9 ^b	
Histologic Data					
IgM positivity	55 (44%)	44 (41%)	11 (52%)	0.4 ^b	
IgG positivity	29 (23%)	20 (19%)	9 (43%)	0.02 ^b	0.221 ^h
C3 positivity	93 (74%)	74 (71%)	19 (91%)	0.04 ^b	0.189 ^h
C1q positivity	18 (14%)	14 (13%)	4 (19%)	0.5 ^b	
M1 score ^j	105 (83%)	87 (83%)	18 (86%)	0.9 ^b	
E1 score ^j	12 (10%)	10 (10%)	2 (10%)	0.9 ^b	
S1 score ^j	62 (49%)	50 (48%)	12 (57%)	0.4 ^b	
T score ^j				0.006 ^b	0.289 ^e
T1 score	34 (27%)	26 (25%)	8 (38%)		
T2 score	5 (4%)	2 (2%)	3 (14%)		
Crescents ^j	11 (9%)	10 (10%)	1 (6%)	0.7 ^b	
Arterial intimal fibrosis	62 (49%)	47 (41%)	15 (71%)	0.03	0.191 ^h
Arteriolar hyalinosis	48 (38%)	38 (36%)	10 (48%)	0.09	
Microangiopathic lesions	36 (29%)	28 (27%)	8 (38%)	0.1 ^b	
Acute	23 (18%)	18 (17%)	5 (24%)	0.3 ^b	
Chronic	20 (16%)	13 (12%)	7 (33%)	0.01	0.259 ^h
C4dG IHC positivity	35 (28%)	19 (18%)	16 (76%)	<0.001	0.482 ^e

Note: Values for categorical variables expressed as number (percent); for continuous variables as mean ± standard deviation, or for non-normally distributed variables, median [interquartile range]. Association is measured with eta-squared or Cramér V coefficient and interpreted as ^hsmall, ^emedium, and ^flarge, as previously described.^{35,36} Abbreviations: C4dA, arteriolar C4d; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HTN, hypertension; IgA, immunoglobulin A; IHC, immunohistochemistry; RAS, renin-angiotensin system.

^at test.

^bChi-square test or Fisher exact test.

^cDefined as systolic blood pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg or use of antihypertensive medication.

^dDiagnosed 1 year before nephrology consultation.

^eMann-Whitney.

^fDyslipidemia defined as the presence of either total cholesterol ≥ 200 mg/dL, low-density lipoprotein cholesterol ≥ 130 mg/dL, high-density lipoprotein cholesterol < 40 mg/dL in men and < 50 mg/dL in women, triglycerides ≥ 150 mg/dL, or current use of antidiabetic medication.

^gScoring is according to Oxford MEST-C classification: M1, mesangial score > 0.5; S1, segmental glomerulosclerosis present; E1, endocapillary hypercellularity present; T1-2, tubular atrophy/interstitial fibrosis 26% to 50% (T1) or >50% (T2); crescents, cellular/fibrocellular crescents present in ≥ 1 glomerulus.

Associations of C4dA and C4dG With Baseline Characteristics

C4dA positivity (C4dA IHC) was present in 21 patients (17%; Fig 1). Furthermore, C4dA IHC was significantly

associated with lower eGFR, serum IgA level, and serum C3:C4 ratio and higher proteinuria and MAP, as well as with the presence of IgG, C3, T1 and T2, arterial intima fibrosis, chronic microangiopathy, and C4dG IHC in the

Table 2. Associations of Baseline Characteristics With Progressive Kidney Disease

	HR (95% CI)	P
Clinical Data		
Age, per 1 y older	1.027 (1.004-1.050)	0.02
Female sex	1.375 (0.651-2.904)	0.4
HTN at biopsy ^a	7.722 (2.350-25.372)	0.001
Mean arterial pressure, per 1 mm Hg greater	1.053 (1.033-1.072)	<0.001
Previous HTN ^b	2.429 (1.211-4.872)	0.01
RAS blockade	1.703 (0.772-3.330)	0.1
Previous macroscopic hematuria	0.721 (0.328-1.583)	0.4
eGFR, per 1 mL/min/1.73 m ² greater	0.942 (0.926-0.958)	<0.001
Proteinuria, per 1 g/d greater	1.296 (1.169-1.436)	<0.001
Serum IgA, per 1 mg/dL greater	0.997 (0.995-1.002)	0.2
Serum C3:C4 ratio, per 1 unit greater	0.632 (0.437-0.915)	0.02
Dyslipidemia ^c	2.069 (1.032-4.149)	0.04
Statin therapy	1.481 (0.701-3.135)	0.3
Smoker	3.574 (1.732-7.375)	0.001
Histologic Data		
IgM positivity	2.137 (1.044-4.372)	0.04
IgG positivity	0.935 (0.402-2.172)	0.9
C3 positivity	1.345 (0.549-3.294)	0.5
C1q positivity	0.931 (0.326-2.664)	0.9
M1 score (vs M0)	1.249 (0.436-3.576)	0.7
S1 score (vs S0)	0.822 (0.410-1.649)	0.6
E1 score (vs E0)	3.189 (1.307-7.781)	0.01
T score		
T0 score	1.000 (reference)	
T1 score	15.449 (5.860-40.725)	<0.001
T2 score	26.252 (7.007-98.358)	<0.001
Crescents	4.857 (2.079-11.349)	<0.001
Arterial intima fibrosis	3.418 (1.532-7.629)	0.003
Arteriolar hyalinosis	4.355 (1.681-11.282)	0.002
Microangiopathic lesions	3.930 (1.777-8.691)	0.001
Acute microangiopathy	2.889 (1.307-6.388)	0.009
Chronic microangiopathy	2.983 (1.353-6.576)	0.007
C4dG IHC positivity	2.627 (1.311-5.265)	0.006
C4dA IHC positivity	4.024 (1.962-8.250)	<0.001

Note: Progressive kidney disease defined as decline of at least 50% in eGFR or reaching kidney failure during the follow-up period. M1, mesangial score > 0.5; S1, segmental glomerulosclerosis present; E1, endocapillary hypercellularity present; T1-2, tubular atrophy/interstitial fibrosis 26% to 50% (T1) or >50% (T2); crescents, cellular/fibrocellular crescents present in ≥1 glomerulus.

Abbreviations: C4dA, arteriolar C4d; C4dG, glomerular C4d; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; HTN, hypertension; IgA, immunoglobulin A; IHC, immunohistochemistry; RAS, renin-angiotensin system.

^aDefined as defined as systolic blood pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg or use of antihypertensive medication.

^bHypertension diagnosed 1 year before nephrology consultation.

^cDefined as the presence of either total cholesterol ≥ 200 mg/dL, low-density lipoprotein cholesterol ≥ 130 mg/dL, high-density lipoprotein cholesterol < 40 mg/dL in men and <50 mg/dL in women, triglycerides ≥ 150 mg/dL, or current use of antidiabetic medication.

biopsy (Table 1). Based on previously proposed criteria,^{35,36} the strength of association of C4dA IHC with

eGFR, MAP, IgA, and T1 and T2 is medium, whereas for the other variables it is considered small.

Regarding microangiopathic lesions, 4 cases presented with C4dA and acute and chronic microangiopathic lesions (CKD stages 2, 3, 4, and 5). Three C4dA-positive cases had chronic but not acute microangiopathic arteriolar lesions (CKD stages 2, 4, and 5), while only 1 case presented with C4dA positivity and acute but not chronic microangiopathic lesions (CKD stage 4).

Patients with positive C4dG IHC had significantly higher baseline proteinuria compared with patients without (Table S2). Furthermore, C4dG IHC was associated with the presence of IgM, IgG, T1, and T2 in the biopsy specimen (Table S2).

Associations of C4dA and C4dG With Outcomes

C4dA IHC was associated with progressive kidney disease (Table 2). This effect remained significant after adjusting for microangiopathic lesions, arterial intima fibrosis, arteriolar hyalinosis, and proteinuria, separately (Table 3). Kaplan-Meier plots (Fig 2) show longer survival for patients negative for both C4dA and C4dG IHC compared with patients positive for 1 of these markers or for both (Fig 2; $P < 0.001$ by log-rank test).

Table 2 displays all variables that were significantly associated with progressive kidney disease in Cox regression analyses. Multivariable models were constructed to evaluate and compare the associations of C4dA and C4dG IHC with progressive kidney disease while controlling for other significant variables. Following the first approach described in Methods for multivariable analysis, the final model included the variables eGFR, IgM positivity, MAP, crescents, and C4dA IHC, but not C4dG IHC (Table S3). The second approach described in Methods for multivariable analysis resulted in the models presented in Table 3. Both C4dA and C4dG IHC were associated with progressive kidney disease (crude model, model 1). In the final model (model 4), C4dA IHC remained significant, while C4dG IHC did not ($P = 0.05$), and the Akaike information criterion was slightly lower for the C4dA IHC model. Harrell concordance indexes were calculated for both final models and their values were validated using bootstrapping. Slightly higher values were obtained for both the C4dA IHC model (0.950; 95% CI, 0.923-0.974) than for the C4G IHC model (0.943; 95% CI, 0.926-0.970), but without reaching a statistically significant difference. Models 4 for C4dA IHC and C4dG IHC in Table 3 were re-estimated with patients with a follow-up longer than 1 year. In these models the significance of C4dA (HR, 3.99; 95% CI, 1.25-12.85; $P = 0.02$), but not C4dG IHC (HR, 2.30; 95% CI, 0.91-5.83; $P = 0.08$), was maintained.

Furthermore, likelihood ratio tests were used to compare crude models (simple Cox models with C4dA or C4dG) with the model that included both C4dA and C4dG as covariates. The rejection of H_0 when comparing the simple C4dG model




Figure 1. Kidney tissue from patients with immunoglobulin A nephropathy (IgAN) was stained for the presence of C4d through immunohistochemistry (IHC). Both glomerular (C4dG) and arteriolar (C4dA) staining was evaluated. (A) Negative C4dA IHC, (B) negative C4dG IHC, (C) positive C4dA IHC, and (D) positive C4dG IHC.

with the model that included both markers ($P = 0.01$) indicates that C4dA offers a statistically significant improvement in the survival model with C4dG alone. However, when comparing the C4dA-only model with the 2-marker model, the test indicates that given the information provided by C4dA IHC, the added value of C4dG IHC is not statistically significant ($P = 0.3$).

Discussion

In IgAN, accurate risk stratification at diagnosis for kidney disease progression remains a challenge. The major finding of the current study is that C4dA deposition is associated with disease progression in IgAN. This association was observed in both unadjusted and adjusted models using 2

different approaches. Moreover, C4dA had a mildly stronger association with disease progression than C4dG. These results provide evidence that C4dA in the kidney biopsy specimen is a biomarker for IgAN progression.

Deposition of C4d is a widely used biomarker for complement activation because C4d has a long half-life given that it remains covalently bound to surfaces.³⁷ Although recently challenged,^{38,39} the paradigm of C4d as a split product without any described physiologic activity or specific receptor still remains. In IgAN, C4dG is the result of activation of the lectin pathway; however, this has not been proven for C4dA. The lectin pathway has recently been shown to be activated by the cholesterol crystals in atherosclerosis, a possible explanation for the presence of C4dA.⁴⁰ Other potential triggers for vascular

Table 3. Multivariable Cox Regression Analysis: Association of C4dA IHC, as Compared to C4dG IHC, With Progressive Kidney Disease

Model	C4dA IHC			C4dG IHC		
	HR (95% CI)	P	AIC	HR (95% CI)	P	AIC
1	4.024 (1.962-8.250)	<0.001	281.19	2.627 (1.311-5.265)	0.006	286.36
2	3.531 (1.608-7.752)	0.002	230.05	1.382 (0.639-2.989)	0.4	238.17
3	2.381 (1.006-5.634)	0.05	194.03	1.798 (0.807-4.008)	0.2	195.70
4	3.179 (1.331-7.592)	0.009	194.83	2.135 (0.988-4.613)	0.05	197.51

Note: Data are presented as HR plus 95% CI and AIC. Progressive kidney disease defined as decline of at least 50% in eGFR or progression to kidney failure during the follow-up period. Model 1: crude (C4dA IHC or C4dG IHC). Model 2: adjusted for histologic biomarkers: T1, T2, and C1 to C2. Model 3: adjusted for clinical variables: smoking, eGFR, and MAP at the time of biopsy. Model 4: adjusted for baseline variables: C1-C2, MAP, and eGFR.

Abbreviations: AIC, Akaike information criterion; C4dA, arteriolar C4d; C4dG, glomerular C4d; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IgA, immunoglobulin A; IHC, immunohistochemistry; MAP, mean arterial pressure.




Figure 2. Kaplan-Meier analysis of kidney survival according to arteriolar C4d (C4dA) immunohistochemistry (IHC) and glomerular C4d (C4dG) IHC. (A) C4dA-negative versus C4dA-positive. (B) C4dG-negative versus C4dG-positive. (C) Both C4dA- and C4dG-negative versus either C4dA-positive only or C4dG-positive only versus both C4dA- and C4dG-positive. Kidney survival defined as not reaching the kidney disease progression end point (decline of at least 50% in glomerular filtration rate or progression to kidney failure).

C4d deposition include microvascular injury due to hypertension⁴¹ and intravascular cellular debris or injured endothelium.²⁴

However, a role for the classical pathway has recently been suggested because C1q and C4d colocalize in glomerular capillaries and arterioles of IgAN biopsy specimens.²⁵ We did not find this colocalization in glomeruli or arterioles. Nevertheless, C4dG IHC positivity, but not C4dA IHC, is associated with IgM deposition, suggesting complement activation by immunocomplexes in glomeruli but not in vessels. Further studies should focus on whether C4dA is a marker of immune complex-mediated injury in

IgAN or if it is the consequence of nonspecific proatherosclerotic stimuli and/or vascular endothelial injury due to progression of CKD.

In this cohort, we tested the strength of C4dA IHC against the most potent clinical and histologic prognostic variables. A previous large cohort study established a prediction model for disease progression in IgAN at the time of kidney biopsy.³⁴ In line with these findings, the current study used most of the risk factors previously described for the regression analysis and C4dA remained significantly associated with outcome after adjustment. This association was also maintained in a subgroup analysis

of patients with at least 1-year follow-up, thereby excluding very advanced cases to mitigate the possibility that C4dA is a marker of advanced damage. After multivariable modeling, eGFR, MAP, and crescents also remained in both final models, but not proteinuria. In IgAN, proteinuria is a well-studied risk factor for progression to kidney failure with replacement therapy.^{34,42} However, the STOP-IgAN trial underscores the finding that progression is not solely dependent on proteinuria.⁵

Besides confirming the association between C4dG IHC and progressive disease,^{7,8,31} the current study also compared the use of C4dA IHC with C4dG IHC as biomarkers in IgAN. Both were associated with kidney disease outcomes, but C4dA IHC had a stronger association with progressive kidney disease than did C4dG IHC. Importantly, because C4dG is widely accepted as a prognostic marker in IgAN, C4dA analysis could be easily added without the need for another procedure while still improving its predictive power.

The vascular compartment is not included in the Oxford classification for IgAN because it was shown to not predict kidney disease outcomes in the original and validation cohorts.^{17,28} However, vascular lesions, such as arterial intima fibrosis, arteriolar hyalinosis, and microangiopathy, have recently been shown to be associated with worse outcome.^{18,23,25} In particular, microangiopathic lesions have been proposed to be incorporated in the classification.^{22,23} Interestingly, C4d has been shown to be a reliable general marker for thrombotic microangiopathy in various kidney diseases,²⁴ including IgAN.²⁵ Our results regarding the prevalence and significance of microangiopathy in IgAN are in line with those of previous studies.^{23,25} Although C4d showed a correlation with microangiopathic lesions in this study, the concept of C4d as a common denominator in thrombotic microangiopathy could not be demonstrated. However, these differences might also be explained by the relatively lower number of acute lesions in our study and the fact that our evaluation for microangiopathic lesions focused only on arterioles and not on the combination with glomeruli as in these previous studies.^{24,25} In accordance with others,¹⁸ our data show that arteriolar hyalinosis and arterial intima fibrosis predict progressive disease in IgAN. Notably, C4dA remained associated with outcome even after adjusting for the presence of these vascular lesions. Altogether, the current study demonstrates the importance of vascular disease in IgAN and underscores the rationale that the clinical approach should go beyond proteinuria (as well as eGFR and hypertension) analysis to manage this disease.^{4,3}

The current study has both limitations and strengths. This is a single-center retrospective cohort study; furthermore, very advanced IgAN cases were included, limiting the long-term predictive value of C4dA IHC. Nevertheless, in a subanalysis without these cases, C4dA remained significantly associated with kidney disease outcomes. In addition, we did not determine the incremental value of

C4dA over validated risk prediction models for disease progression due to the limited sample size and patient heterogeneity.³⁴ Moreover, the underlying mechanism for C4d deposition in vessels remains to be established. We acknowledge that the current findings are limited to detection of C4d by IHC and therefore cannot be fully extrapolated to the presence of the molecule per se. Immunofluorescence for C4d detection remains the current gold standard. However, although differences may exist between IHC and immunofluorescence, these might not be as significant as generally claimed.^{31,44,45} Last, due to the focal nature of C4d deposition, potential misclassification cannot be excluded.

However, the strengths of the current study include histologic assessment by 3 masked independent experts, use of a hard and clinically relevant outcome (disease progression), and the extensive statistical analysis that involved 2 different approaches for C4d analysis in IgAN.

In conclusion, our study shows that C4dA IHC deposition can be used as a biomarker for IgAN progression. These findings offer new options for the inclusion of C4d staining in biomarker panels in IgAN and provide new data for the importance of the vascular compartment in this disease. We propose that C4d analysis in IgAN not be restricted to glomeruli but extended to vessels because this is a powerful, inexpensive, and easy-to-perform biomarker of disease progression.

Supplementary Material

Supplementary File (PDF)

Table S1: Duration of follow-up according to CKD stage.

Table S2: Patient baseline characteristics and C4dG IHC status.

Table S3: Cox regression analyses with progressive kidney disease as the end point.

Article Information

Authors' Full Names and Academic Degrees: Bernardo Faria, MD, Pedro Canão, MD, Qingqing Cai, MD, PhD, Carla Henriques, PhD, Ana Cristina Matos, PhD, Felix Poppelaars, MD, PhD, Mariana Gaya da Costa, MD, PhD, Mohamed R. Daha, PhD, Roberto Silva, MD, Manuel Pestana, MD, PhD, and Marc A. Seelen, MD, PhD.

Authors' Affiliations: Nephrology and Infectious Disease R&D Group, INEB, Institute of Investigation and Innovation in Health (i3S), University of Porto, Porto, Portugal (BF, MP); Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (BF, QC, FP, MGdC, MRD, RS, MAS); Department of Anatomic Pathology, Centro Hospitalar Universitário São João, Porto (PC); School of Technology and Management, Polytechnic Institute of Viseu, Viseu (CH, ACM); Centre for Mathematics, University of Coimbra (CMUC), Coimbra (CH); Centre for Research in Digital Services and CISeD, Viseu, Portugal (ACM); Department of Nephrology, University of Leiden, Leiden University Medical Center, Leiden, the Netherlands (MRD); and Division of Nephrology, Centro Hospitalar Universitário São João and Department of Medicine, Faculty of Medicine of Porto University, Porto, Portugal (MP).

Address for Correspondence: Bernardo Faria, MD, Nephrology and Infectious Diseases Research and Development Group,

Institute of Investigation and Innovation in Health (i3S), University of Porto, Al. Professor Hernâni Monteiro 4200-319 Porto, Portugal. E-mail: faria_bernardo@yahoo.com

Authors' Contributions: Research idea and study design: BF, PC, QC, RS; data acquisition: BF, PC, QC, RS; data analysis/interpretation: BF, PC, QC, CH, ACM, FP, MGdC, MRD, RS, MP, MAS; statistical analysis: CH, ACM; supervision or mentorship: FP, MRD, MP, MAS. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

Support: The work that led to this article was supported by a grant from the European Renal Association–European Dialysis and Transplantation Association on behalf of its Research Fellowship Program. Additionally, this work is financed by national funds through FCT (Fundação para a Ciência e Tecnologia, IP) under the project UID/Multi/04016/2019. This work was partially supported by the Centre for Mathematics of the University of Coimbra–UID/MAT/00324/2019, funded by the Portuguese Government through FCT/MEC and co-funded by the European Regional Development Fund through the Partnership Agreement PT2020. Funders of this study had no role in study design; data collection, analysis, or reporting; or the decision to submit for publication.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Acknowledgements: We thank Prof Fátima Carneiro for facilitating the access to the Centro Hospitalar Universitário São João's Kidney Biopsy Bank, Anita Meter-Arkema for excellent technical assistance, and the Instituto Politécnico de Viseu, and CISED for support.

Prior Presentation: Aspects of this work were presented in abstract form at the 17th European Meeting on Complement in Human Disease; Madrid, Spain; September 14-17, 2019.

Peer Review: Received August 12, 2019. Evaluated by 3 external peer reviewers, with direct editorial input from the Pathology Editor, a Statistics/Methods Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form March 10, 2020.

References

- Wyatt RJ, Julian BA. IgA nephropathy. *N Engl J Med*. 2013;368(25):2402-2414.
- Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy. *Semin Nephrol*. 2008;28:4-9.
- Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. *Nephrol Dial Transplant*. 2009;24(12):3694-3701.
- Floege J, Barbour SJ, Catran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2019;95(2):268-280.
- Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. *N Engl J Med*. 2015;373(23):2225-2236.
- Coppo R. C4d deposits in IgA nephropathy: where does complement activation come from? *Pediatr Nephrol*. 2017;32(7):1097-1101.
- Segarra A, Romero K, Agraz I, et al. Mesangial C4d deposits in early IgA nephropathy. *Clin J Am Soc Nephrol*. 2018;13(2):258-264.
- Faria B, Henriques C, Matos AC, Daha MR, Pestana M, Seelen M. Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression. *Clin Exp Immunol*. 2015;179(2):354-361.
- Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. *J Am Soc Nephrol*. 2006;17(6):1724-1734.
- Gaya da Costa M, et al. The lectin pathway in renal disease: old concept and new insights. *Nephrol Dial Transplant*. 2018;33(12):2073-2079.
- Segarra-Medrano A, Carnicer-Caceres C, Valtierra-Carmeno N, et al. Study of the variables associated with local complement activation in IgA nephropathy. *Nefrologia*. 2017;37(3):320-329.
- Onda K, Ohi H, Tamano M, et al. Hypercomplementemia in adult patients with IgA nephropathy. *J Clin Lab Anal*. 2007;21(2):77-84.
- Kiryuk K, Novak J. The genetics and immunobiology of IgA nephropathy. *J Clin Invest*. 2014;124(6):2325-2332.
- Tortajada A, Gutiérrez E, Goicoechea de Jorge E, et al. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. *Kidney Int*. 2017;92(4):953-963.
- Zipfel PF, Wiech T, Rudnick R, Afonso S, Person F, Skerka C. Complement inhibitors in clinical trials for glomerular diseases. *Front Immunol*. 2019;10:2166.
- Trimarchi H, Barratt J, Catran DC, et al; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. *Kidney Int*. 2017;91(5):1014-1021.
- Trimarchi H, Barratt J, Monteiro RC, Feehally J. IgA nephropathy: "state of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description. *Kidney Int*. 2019;95(4):750-756.
- Zhang Y, Sun L, Zhou S, et al. Intrarenal arterial lesions are associated with higher blood pressure, reduced renal function and poorer renal outcomes in patients with IgA nephropathy. *Kidney Blood Press Res*. 2018;43(2):639-650.
- Kovács T, Vas T, Kovesdy CP, et al. Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy. *Clin Kidney J*. 2013;6(4):395-401.
- Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. *Nephrol Dial Transplant*. 2000;15(1):34-42.
- Yamamoto R, Nagasawa Y, Shoji T, et al. Cigarette smoking and progression of IgA nephropathy. *Am J Kidney Dis*. 2010;56(2):313-324.
- El Karoui K, Hill GS, Karras A, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. *J Am Soc Nephrol*. 2012;23(1):137-148.
- Cai Q, Shi S, Wang S, et al. Microangiopathic lesions in IgA nephropathy: a cohort study. *Am J Kidney Dis*. 2019;74(5):629-639.
- Chua JS, Baelde HJ, Zandbergen M, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. *J Am Soc Nephrol*. 2015;26(9):2239-2247.
- Chua JS, Zandbergen M, Wolterbeek R, et al. Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. *Mod Pathol*. 2019;32(8):1147-1157.
- Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612.

27. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. *Am J Kidney Dis.* 2014;64(6):821-835.
28. Cattran DC, Coppo R, Cook HT, et al; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. *Kidney Int.* 2009;76(5):534-545.
29. Jennette JC, D'Agati VD, Olson JL, Silva FG. *Heptinstall's Pathology of the Kidney*. 7th ed. Philadelphia, PA: Wolters Kluwer; 2014.
30. Wallace WD, Naini BV. *Practical Atlas of Transplant Pathology*. 1st ed. Cham, Switzerland: Springer; 2016.
31. Espinosa M, Ortega R, Sánchez M, et al. Spanish Group for Study of Glomerular Diseases (GLOSEN). Association of C4d deposition with clinical outcomes in IgA nephropathy. *Clin J Am Soc Nephrol.* 2014;9(5):897-904.
32. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med.* 1996;15(4):361-387.
33. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. *Stat Med.* 2004;23(13):2109-2123.
34. Barbour SJ, Coppo R, Zhang H, et al. International IgA Nephropathy Network. Evaluating a new international risk-prediction tool in IgA nephropathy. *JAMA Intern Med.* 2019;179(7):942-952.
35. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
36. Kim H-Y. Statistical notes for clinical researchers: chi-squared test and Fisher's exact test. *Restor Dent Endod.* 2017;42(2): 152-155.
37. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. *Kidney Int.* 2012;81(7):628-639.
38. Hofer J, Forster F, Isenman DE, et al. Ig-like transcript 4 as a cellular receptor for soluble complement fragment C4d. *FASEB J.* 2016;30(4):1492-1503.
39. Battin C, De Sousa Linhares A, Paster W, et al. Neuropilin-1 acts as a receptor for complement split products. *Front Immunol.* 2019;10:2209.
40. Pilely K, Rosbjerg A, Genster N, et al. Cholesterol crystals activate the lectin complement pathway via ficolin-2 and mannose-binding lectin: implications for the progression of atherosclerosis. *J Immunol.* 2016;196(12):5064-5074.
41. Batal I, Girit A, Zeevi A, et al. Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney. *Mod Pathol.* 2008;21(12):1490-1498.
42. Thompson A, Carroll K, Inker L, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. *Clin J Am Soc Nephrol.* 2019;14(3):469-481.
43. Gutierrez E. IgA nephropathy: is a new approach beyond proteinuria necessary? *Pediatr Nephrol.* 2019;34(5): 921-924.
44. Troxell ML, Weintraub LA, Higgins JP, Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. *Clin J Am Soc Nephrol.* 2006;1(3):583-591.
45. Nadasdy GM, Bott C, Cowden D, Pelletier R, Ferguson R, Nadasdy T. Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies. *Hum Pathol.* 2005;36(11):1178-1185.